Literature DB >> 25568147

Alectinib induces a durable (>15 months) complete response in an ALK-positive non-small cell lung cancer patient who progressed on crizotinib with diffuse leptomeningeal carcinomatosis.

Sai-Hong Ignatius Ou1, Karen R Sommers1, Michele C Azada1, Edward B Garon2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25568147      PMCID： PMC4319629          DOI： 10.1634/theoncologist.2014-0309

Source DB:  PubMed          Journal:  Oncologist        ISSN： 1083-7159


× No keyword cloud information.
  15 in total

1.  Effective crizotinib schedule for brain metastases in ALK rearrangement metastatic non-small-cell lung cancer.

Authors:  Nir Peled; Leor Zach; Ori Liran; Maya Ilouze; Paul A Bunn; Fred R Hirsch
Journal:  J Thorac Oncol       Date:  2013-12       Impact factor: 15.609

2.  High-dose crizotinib for brain metastases refractory to standard-dose crizotinib.

Authors:  Young Hak Kim; Hiroaki Ozasa; Hiroki Nagai; Yuichi Sakamori; Hironori Yoshida; Yoshitaka Yagi; Takashi Nakaoku; Michiaki Mishima
Journal:  J Thorac Oncol       Date:  2013-09       Impact factor: 15.609

3.  High-dose pemetrexed in combination with high-dose crizotinib for the treatment of refractory CNS metastases in ALK-rearranged non-small-cell lung cancer.

Authors:  Leena Gandhi; Jan Drappatz; Nikhil H Ramaiya; Gregory A Otterson
Journal:  J Thorac Oncol       Date:  2013-01       Impact factor: 15.609

4.  ALK inhibitor crizotinib combined with intrathecal methotrexate treatment for non-small cell lung cancer with leptomeningeal carcinomatosis.

Authors:  Hee Kyung Ahn; Boram Han; Su Jin Lee; Taekyu Lim; Jong-Mu Sun; Jin Seok Ahn; Myung-Ju Ahn; Keunchil Park
Journal:  Lung Cancer       Date:  2012-03-03       Impact factor: 5.705

5.  The central nervous system as a sanctuary site in ALK-positive non-small-cell lung cancer.

Authors:  Justin F Gainor; Sai-Hong Ignatius Ou; Jennifer Logan; Lawrence F Borges; Alice T Shaw
Journal:  J Thorac Oncol       Date:  2013-12       Impact factor: 15.609

6.  Alectinib salvages CNS relapses in ALK-positive lung cancer patients previously treated with crizotinib and ceritinib.

Authors:  Justin F Gainor; Carol A Sherman; Kathryn Willoughby; Jennifer Logan; Elizabeth Kennedy; Priscilla K Brastianos; Andrew S Chi; Alice T Shaw
Journal:  J Thorac Oncol       Date:  2015-02       Impact factor: 15.609

7.  First-line crizotinib versus chemotherapy in ALK-positive lung cancer.

Authors:  Benjamin J Solomon; Tony Mok; Dong-Wan Kim; Yi-Long Wu; Kazuhiko Nakagawa; Tarek Mekhail; Enriqueta Felip; Federico Cappuzzo; Jolanda Paolini; Tiziana Usari; Shrividya Iyer; Arlene Reisman; Keith D Wilner; Jennifer Tursi; Fiona Blackhall
Journal:  N Engl J Med       Date:  2014-12-04       Impact factor: 91.245

8.  Leptomeningeal carcinomatosis in non-small-cell lung cancer patients: impact on survival and correlated prognostic factors.

Authors:  Su Jin Lee; Jung-Il Lee; Do-Hyun Nam; Young Chan Ahn; Jung Ho Han; Jong-Mu Sun; Jin Seok Ahn; Keunchil Park; Myung-Ju Ahn
Journal:  J Thorac Oncol       Date:  2013-02       Impact factor: 15.609

9.  Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.

Authors:  Alice T Shaw; Dong-Wan Kim; Kazuhiko Nakagawa; Takashi Seto; Lucio Crinó; Myung-Ju Ahn; Tommaso De Pas; Benjamin Besse; Benjamin J Solomon; Fiona Blackhall; Yi-Long Wu; Michael Thomas; Kenneth J O'Byrne; Denis Moro-Sibilot; D Ross Camidge; Tony Mok; Vera Hirsh; Gregory J Riely; Shrividya Iyer; Vanessa Tassell; Anna Polli; Keith D Wilner; Pasi A Jänne
Journal:  N Engl J Med       Date:  2013-06-01       Impact factor: 91.245

10.  CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1-2 study.

Authors:  Takashi Seto; Katsuyuki Kiura; Makoto Nishio; Kazuhiko Nakagawa; Makoto Maemondo; Akira Inoue; Toyoaki Hida; Nobuyuki Yamamoto; Hiroshige Yoshioka; Masao Harada; Yuichiro Ohe; Naoyuki Nogami; Kengo Takeuchi; Tadashi Shimada; Tomohiro Tanaka; Tomohide Tamura
Journal:  Lancet Oncol       Date:  2013-04-30       Impact factor: 41.316
View more
  17 in total

1.  ALK on my mind: alectinib takes an early lead in managing intracranial disease in non-small cell lung cancer with ALK rearrangements.

Authors:  Phu N Tran; Samuel J Klempner
Journal:  Ann Transl Med       Date:  2017-04

2.  Sequencing ALK inhibitors: alectinib in crizotinib-resistant patients, a phase 2 trial by Shaw et al.

Authors:  Laura Mezquita; Benjamin Besse
Journal:  J Thorac Dis       Date:  2016-11       Impact factor: 2.895

3.  Alectinib-a new chapter in the management of ALK-positive lung cancer.

Authors:  Justin F Gainor
Journal:  Transl Lung Cancer Res       Date:  2016-06

4.  Pooled Analysis of CNS Response to Alectinib in Two Studies of Pretreated Patients With ALK-Positive Non-Small-Cell Lung Cancer.

Authors:  Shirish M Gadgeel; Alice T Shaw; Ramaswamy Govindan; Leena Gandhi; Mark A Socinski; D Ross Camidge; Luigi De Petris; Dong-Wan Kim; Alberto Chiappori; Denis L Moro-Sibilot; Michael Duruisseaux; Lucio Crino; Tommaso De Pas; Eric Dansin; Antje Tessmer; James Chih-Hsin Yang; Ji-Youn Han; Walter Bordogna; Sophie Golding; Ali Zeaiter; Sai-Hong Ignatius Ou
Journal:  J Clin Oncol       Date:  2016-10-31       Impact factor: 44.544

5.  Alectinib Dose Escalation Reinduces Central Nervous System Responses in Patients with Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer Relapsing on Standard Dose Alectinib.

Authors:  Justin F Gainor; Andrew S Chi; Jennifer Logan; Ranliang Hu; Kevin S Oh; Priscilla K Brastianos; Helen A Shih; Alice T Shaw
Journal:  J Thorac Oncol       Date:  2015-12-18       Impact factor: 15.609

Review 6.  Treatment Optimization for Brain Metastasis from Anaplastic Lymphoma Kinase Rearrangement Non-Small-Cell Lung Cancer.

Authors:  Wenhui Wang; Xin Sun; Zhouguang Hui
Journal:  Oncol Res Treat       Date:  2019-09-17       Impact factor: 2.825

Review 7.  Kinase drug discovery 20 years after imatinib: progress and future directions.

Authors:  Philip Cohen; Darren Cross; Pasi A Jänne
Journal:  Nat Rev Drug Discov       Date:  2021-05-17       Impact factor: 112.288

Review 8.  Mechanisms of Acquired Resistance to ALK Inhibitors and the Rationale for Treating ALK-positive Lung Cancer.

Authors:  Hideko Isozaki; Nagio Takigawa; Katsuyuki Kiura
Journal:  Cancers (Basel)       Date:  2015-04-30       Impact factor: 6.639

Review 9.  Molecular Targeted Therapies for the Treatment of Leptomeningeal Carcinomatosis: Current Evidence and Future Directions.

Authors:  Dae-Won Lee; Kyung-Hun Lee; Jin Wook Kim; Bhumsuk Keam
Journal:  Int J Mol Sci       Date:  2016-07-05       Impact factor: 5.923

Review 10.  Insights into brain metastasis in patients with ALK+ lung cancer: is the brain truly a sanctuary?

Authors:  Gouji Toyokawa; Takashi Seto; Mitsuhiro Takenoyama; Yukito Ichinose
Journal:  Cancer Metastasis Rev       Date:  2015-12       Impact factor: 9.264
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.